J.B. Chemicals & Pharmaceuticals reported its Q4 FY26 financial results, recording revenue of Rs. 904 crores and EBITDA of Rs. 241 crores. While the quarter saw a 5% YoY revenue decline, the company remains focused on post-acquisition integration. Despite temporary headwinds from operational realignments, the firm achieved a 27% EBITDA margin and maintains a positive growth outlook as it harmonizes business practices with its parent entity.
Quarterly Financial Performance
For the fourth quarter ended March 31, 2026, J.B. Chemicals & Pharmaceuticals posted revenues of Rs. 904 crores, reflecting a 5% decrease compared to the same period last year. The company reported an EBITDA of Rs. 241 crores with a margin of 27%. Net profit after tax stood at Rs. 101 crores, while the adjusted net profit reached Rs. 150 crores after accounting for one-off charges and non-cash ESOP costs.
Strategic Business Highlights
The company’s performance was influenced by significant integration activities following a change of control. The India business showed resilience, growing by 2% YoY to Rs. 526 crores for the quarter, with the chronic portfolio outperforming the industry at 19% growth. Conversely, the International Formulations segment experienced a 9% de-growth due to inventory rationalization and logistics constraints, while CDMO revenues declined by 22% against a high base from the previous year.
Future Outlook and Integration
Management characterized the quarter as a transient phase of integration. The company is actively aligning its business policies, credit practices, and operational frameworks with its parent organization. These measures, including the discontinuation of low-margin trade generics, are expected to strengthen the long-term foundation of the business. The company anticipates that core performance will improve progressively from April onward, driven by cost synergies and a healthier business mix.
Source: BSE
